Viatris plans for Ozempic, Wegovy generics amid lawsuit from Novo Nordisk over Wegovy

Vi­a­tris Phar­ma­ceu­ti­cals’ ap­pli­ca­tions for gener­ic op­tions for type 2 di­a­betes drug Ozem­pic and weight loss drug We­govy are now un­der reg­u­la­to­ry re­view, ac­cord­ing to the com­pa­ny’s sec­ond quar­ter pre­sen­ta­tion.

If ap­proved, both would be the first gener­ics to mar­ket for the block­buster drugs.

But No­vo Nordisk has al­ready tak­en steps to stop Vi­a­tris from bring­ing a We­govy gener­ic to mar­ket with a law­suit filed in Jan­u­ary in Delaware Dis­trict Court. In court fil­ings, lawyers for No­vo wrote that the law­suit comes from Vi­a­tris’ sub­mis­sion of an ab­bre­vi­at­ed NDA to the FDA for a We­govy gener­ic in­jec­tion pri­or to the patents’ ex­pi­ra­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.